BIO Web Conf.
Volume 14, 2019The 12th International Conference on the Health Effects of Incorporated Radionuclides (HEIR 2018)
|Number of page(s)||3|
|Section||Dosimetry and Dose Assessment: Poster presentation|
|Published online||07 May 2019|
223Ra dichloride incidental inhalation: recommendations to estimate the committed effective dose
Service de protection radiologique des armées, 1bis rue du Lieutenant Raoul Batany, CS500 57, 92141 Clamart Cedex, France
2 Hôpital d’instruction des armées Percy, Service de pharmacie hospitalière, 101 avenue Henri Barbusse BP 406, 92141 Clamart Cedex, France
3 Services de médecine nucléaire, Institut inter-régional de cancérologie , Centre Jean Bernard 72000 Le Mans
et Centre d’Imagerie Scintigraphique d’Eure et Loir, 28300 Le Coudray, France
4 Hôpital d’instruction des armées Sainte Anne, 2 boulevard Ste Anne, BP 600, 83800 Toulon, France
* Corresponding author: firstname.lastname@example.org
223Ra dichloride - Xofigo® (Bayer AG, Germany) - is a therapeutic alpha particle-emitting pharmaceutical used in nuclear medicine for patients with metastatic castration-resistant prostate cancer (mCRPC). The radiopharmaceutical is formulated as a ready-to-use solution (unsealed source) and is administered to patients as an intravenous injection [1-2]. As it is an alpha-emitter, internal contamination is feared. If inhalation contamination is suspected, an adequate special monitoring programme needs to be provided to estimate the committed effective dose. 223Ra internal contamination monitoring can be performed by two methods: in vivo measurements and in vitro measurements (urine of faeces). The purpose of our study was to determine the most appropriate method for individual monitoring of nuclear medicine staff who could have inhaled 223Ra and propose recommendations for committed effective dose assessment.
First, minimum detectable activities (MDA) and scattering factors (SF) of these methods were estimated according, respectively, to the French working group number 5 (GTN5) and EURADOS Guidelines [3-4]. Concerning in vitro analysis, due to the 223Ra short half-life (11.4 d), an adjusted MDA was calculated at the end date of the 24-h sampling to consider transport and sample pre-treatment times (~48h for urine and ~96h for faeces). In vivo measurements were obtained by a bed-type whole-body counter equipped with two coaxial p-type high purity germanium (HPGe) detectors. The counting time was set to 45 min. In vitro measurements were obtained by direct measurement using a gamma spectrometer equipped with one coaxial n-type HPGe detector on 500-mL aliquot portion of the true 24-h urine samples or complete 24h-faeces ashed and dissolved in acid. The counting time was set to 10800 s.
in which e(50) is the effective dose coefficient (5.7 x 10-6 Sv Bq-1) following a unit intake of 223Ra for inhalation (pulmonary absorption parameter “Moderate” and AMAD set to 5 μm by default), F(t) is the value of the retention or excretion function at time t (in days).
Special monitoring programmes should provide enough data to assess the committed effective dose. That’s why a suitable combination of in vivo measurements and in vitro analyses according to the appropriate biokinetic model would be used.
Figure 1 compares the MDED to an effective dose limit of 1 mSv (workers recording level). It appears that whole body counting (WBC) is sensitive enough only the day following incorporation. Although urine samples analysis has a low SF, it should be used only in a case of a major contamination (>15 mSv). Thus, due to its rapidity and its non-invasiveness, WBC (with HPGe detector) should be the first choice to estimate the committed effective dose. However, after 24 h, sufficient sensitivity can only be reached by true 24-h faeces samples analyses (up to 8 days after contamination). Thus, in that case, despite its main drawbacks (excretion fluctuation, staff reluctance, higher SF…), this method should be associated with WBC to estimate the committed effective dose.
MDED after acute inhalation of 223Ra as aerosol (type M; 5μm AMAD) with whole-body counting, urinary or faecal analyses and SF associated to each method.
- Bayer AG. Annex I Summary of product characteristics. Xofigo: EPAR Product Information. (2017). [Google Scholar]
- Wadas, T. J. Pandya, D. N. Solingapuram Sai, K. K. and Mintz, A. AJR Am J Roentgenol. 203(2), 253-260 (2014). [CrossRef] [PubMed] [Google Scholar]
- Groupe de travail de normalisation n°5 (GTN5) du Centre Technique d’Homologation de l’Instrumentation de Radioprotection (CTHIR) (1994). [Google Scholar]
- Castellani, C. M. Marsh, J. W. Hurtgen, C. Blanchardon, E. Berard, P. Giussani, A. Lopez, M-A. EURADOS Report 2013-011. (2013) [Google Scholar]
© The Authors, published by EDP Sciences, 2019
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.